Send us Fan Mail Gene regulation through RNAs, the neurobiology of opioid addiction, and how psychedelics affect drug-seeking by modulating inflammation and plasticity. Not medical advice. TOPICS DISCUSSED: Gene regulation basics: DNA transcribes to RNAs, including non-coding types like microRNAs that inhibit mRNA translation into proteins, influencing up to 60% of the proteome. Non-coding RNAs in neuroplasticity: MicroRNAs and circular RNAs regulate synaptic changes, with activity-induced ones like miR-485-5p linked to rapid responses in drug cue memory and addiction reinforcement. Opioid addiction models: Rats self-administer heroin or fentanyl via levers, showing compulsive seeking; fentanyl’s higher potency drives faster learning but similar long-term effects to heroin when doses are equated. Differences between opioids: Heroin and fentanyl both activate mu-opioid receptors for euphoria and dopamine release, but fentanyl lingers longer; no major behavioral differences in seeking once potency is matched. Psilocybin’s effects on addiction: A single psilocybin dose post-abstinence reduces heroin-seeking in rats by dampening neuroinflammation in brain regions like the nucleus accumbens and prefrontal cortex. Brain Inflammation: Opioids induce pro-inflammatory changes via cytokines like IL-17A and pathways like TNF-alpha, leading to glial activation and blood-brain barrier leaks; psilocybin counters this. MicroRNA biomarkers: Blood microRNAs reflect gene expression patterns tied to disease states, with potential to predict opioid relapse risk, treatment response, or neonatal withdrawal severity non-invasively. Future research: Ongoing work links psilocybin’s serotonin 2A activation to anti-inflammatory gene changes, plus human studies on microRNAs for personalized addiction treatments. ABOUT THE GUEST: Stephanie Daws, PhD is an associate professor at Temple University in the Center for Substance Abuse Research and Department of Neurosciences, where she researches mechanisms of drug-seeking behavior with a focus on opioids and psychedelics. RELATED EPISODE: M&M 2 | Psilocybin, LSD, Ketamine, Inflammation & Novel Psychedelic Medicines | Charles Nichols Support the show Support my work: Good Chemistry: Personalized, science-based health consulting. Work with Dr. Nick Jikomes directly. Affiliate Partners: Visit this link to see my affiliate partners and get discounts codes for products & services to support health. For all the ways you can support my efforts.
Audio and video play straight from the show's own hosting. PodSubs stores and serves no media.
Transcript
From the show. Tap a time to play from there.
Nick JikomesWhether food, drugs, or ideas, what you consume influences who you become. On the Mind & Matter podcast, we learn together from the best scientists and thinkers alive today about how your mind-body reacts to what you feed it. Before starting Mind & Matter, I spent 10 years in academia doing scientific research. I got a PhD in neuroscience, where I focused on neuroendocrinology and the neurobiology of behavior, and before that, I specialized in molecular, developmental, and evolutionary genetics. I use my scientific background to help parse and translate the information that guests share on the podcast. In addition to the podcast, I write long-form, written content inspired by the show, where I integrate what I've learned across episodes. I also have a free weekly newsletter where I provide you with upcoming guests, share links and provide commentary on scientific studies and research that I'm reading, and more. Visit mindandmatter.substack.com to find all of my content.
Nick JikomesYou are about to listen to the full episode, but there will be one to two short ads immediately following this before the conversation. If you would like to hear ad-free episodes and get early access before they release more widely, become a paid subscriber at the Mind & Matter substack at mindandmatter.substack.com. Becoming a paid subscriber is a way to directly support my efforts, allowing me to make more episodes and higher quality episodes. helping to free up my time so that I can spend more of it on doing research and synthesizing results from the podcast and from the literature so that I can do more things like writing on the Substack, putting more content into the newsletter, and getting these things out more frequently. So if you want to support the show and get ad-free episodes, go to mindandmatter.substack.com. Hey, everyone. I'm going to take just a minute to tell you about SporesMD, your trusted source for premium mushroom products designed for research and educational purposes.
Nick JikomesAt sporesmd.com you can discover pharmaceutical grade mushroom liquid cultures featuring dozens of unique strains of psilocybe mushroom species ideal for microscopy studies and mycology enthusiasts. They also offer culinary liquid cultures for gourmet mushroom enthusiasts plus innovative options like nootropic scummies and amanita muscaria tinctures, all produced in ISO 7 certified clean rooms with rigorous testing for viability, sterility, and purity. With a 100% satisfaction guarantee, SporesMD ensures high-quality products free from contaminants and without traces of controlled substances. Whether you're interested in scientific exploration or simply curious about the fascinating world of fungi, SporesMD provides reliable tools to support your interests, always in compliance with applicable laws.
Nick JikomesHead to sporesmd.com today and use the discount code TRICOMES. T-R-I-K-O-M-E-S for 20% off your purchase today. So go to sporesmd.com and check out what they have. Thank you for joining me.
Stephanie DawsThank you for inviting me.
Nick JikomesDo you want to start off by just telling everyone who you are and what your lab studies?
Stephanie DawsSure. I am an associate professor at Temple University, and I am in the Center for Substance Abuse Research, also the Department of Neurosciences. The focus of my lab is on understanding mechanisms that contribute to drug-seeking behavior. We have a big emphasis in our lab on opioid seeking behavior. And a reason behind that is because the opioid epidemic has been taking many, many lives from individuals in the United States for decades now. Where I am in Philadelphia, I am in one of the areas of the city that has very high rates of drug use. And there are many people in this community that are impacted by the opioid epidemic.
Nick JikomesAnd we'll get into some of that stuff. But one of the things that you look at in your lab that I haven't covered so much on the podcast is one aspect of how gene regulation happens. So in all of our cells, all of our cells have the same genome. And what makes a skin cell, a skin cell, a brain cell, a brain cell, and so forth is which genes are turned on and off. what parts of the genome are being utilized to make proteins and things that define what a cell is and what a cell does. One of the ways the gene expression is regulated is through something called non-coding RNAs. And I want to give people a sense for some of that stuff because it's really interesting and I haven't covered it too much on the podcast. But then of course, this stuff ties into how some of the neuroplasticity related to drug seeking and reward and all the other things you study actually works.
Nick JikomesSo let's give people a very basic snapshot of gene regulation briefly, and then talk about non-coding RNAs. So when people think about genes and the genome being turned on, being turned off, up and down, what do they need to know in terms of those things and the key difference between, say, the coding regions and the non-coding regions? What does that mean?
Stephanie DawsAh, that's a really big question. So what do people need to know about gene expression? Well, there's a part of RNA called mRNA that is made up of coding regions, and those coding regions will be translated into protein. And once the proteins are made, the proteins do a lot of work in the cell. How gene expression is regulated, there's many facets of this. So for example, there could be epigenetic modifications that control the accessibility of the chromatin, and that determines which genes are going to be expressed. And that is due to the DNA being very tightly wound around histone proteins, or the DNA could be hypermethylated and that causes less of the DNA to be exposed to transcription factors that allow gene expression to occur. My lab, we do study non-coding RNAs and we study them for a variety of reasons.
Stephanie DawsOne is that non-coding RNAs are another way of controlling gene expression, but the primary mechanism of gene expression regulation via non-coding RNAs is by inhibiting translation of mRNA into protein. So microRNAs, they can cause de-adenylation of the poly-A tail of mRNA, and that prevents the mRNA being made into a protein. They can also cause some decay of mRNA, but in mammalian cells, primarily it's prevention of translation occurring.
Nick JikomesGot it. So if we were to just step back for a sec, so like sort of the canonical way that genes work that people learn about in like high school and college, usually in like a one-on-one classes. It's got your DNA. The DNA will be transcribed into mRNA, and then the mRNA will get made into a protein that does something. It might be an enzyme in your liver cells or a synapse protein in your neurons or whatever. But that's not all there is by any stretch of the imagination. So some parts of the genome, some parts of genes get turned into what will eventually become a protein that does something. But there are also RNAs that get made from the DNA that don't then go turn into proteins.
Nick JikomesThey can actually then go back and interact with the genes to control how much protein ultimately gets made. So there's parts of the genome that don't get turned into proteins, they get turned into RNAs that are part of regulating whether or not proteins get made or how much gets made and things like that.
Stephanie DawsCorrect. There's different classes of RNA species. So some have more regulatory functions. Some are going to be made into proteins eventually. We also study another type of non-coding RNA called circular RNAs. And circular RNAs are made from the mRNA that gets spliced. And most of the time, those spliced variants form a circle that doesn't get translated into protein. There are some instances in which the circular RNA does get made into protein because it has many of the components that are present in the protein.
Stephanie DawsBut ultimately, the function of circular RNAs isn't very well established, and they're thought to be more regulatory as well, preventing RNA-binding proteins from interacting with their targets. Also, modulating gene expression of perhaps the linear mRNA that they are derived from. So that's just one example of another non-coding RNA. But many people think of RNA as mRNA, and it's important to recognize that there are many other classes.
Stephanie DawsThere's tRNA, there's piRNAs, there are many other types of RNA species, and they do have different functions in the cell.
Nick JikomesGot it. So DNA can turn into RNA. mRNA is one version, but there's many types of RNAs, as you mentioned. And it sounds like a lot of what defines what they do and how they work is the shape they take. So DNA might be transcribed into mRNA, and it might be just a linear string of mRNA that then goes on to do something like get translated into a protein. But these RNAs can be folded into circles. They can be folded into more complex or exotic shapes. And the folding and the structure of those things will often dictate what exactly they go on to do.
Stephanie DawsYes. That's one way of looking at it. Yes. The conformation of nucleic acids is an area of research that has really jumped off in recent years. So in addition to the conformation of RNA, also the conformation of DNA is something that is being more and more studied because there are ways in which the nucleic acid can fold back on itself. And then you have regions that appear to be very far away from each other, many base pairs away, but because of their confirmation, then they come into interaction with another area and they can also regulate gene expression.
Nick JikomesGot it. So talk a little bit more about micro RNAs. What exactly are micro RNAs and just give us the basics there.
Stephanie DawsOkay, well, microRNAs, as the name says, they're very small pieces of RNA. They're typically between 18 to 24 nucleotides, and they are made from a prime microRNA. The prime microRNA is present, it's transcribed from the DNA, and it has a longer sequence to it, and it also folds back on itself. When the prime microRNA is made into the mature microRNA, then it is trimmed even further and you have this really small sequence.
Stephanie DawsThe microRNA can then interact with mRNA. The interaction is based on a region of the microRNA that has sequence complementarity with the mRNA, and it's typically about six to eight nucleotides long. 6 to 8 nucleotides isn't that much, so you can imagine that one micro RNA can interact with many different sequences of mRNA because it only needs to match up with 6 to 8 nucleotides. We have tens of thousands of genes in our body.
Stephanie DawsSo one microRNA can interact with many mRNA. And the mRNAs are referred to as the target of the microRNA. There's other proteins that are involved in facilitating the interaction between the microRNA and the mRNA. But the end result in mammalian cells is that the poly-A tail of the mRNA will become deadenylated, and that can prevent the initiation of translation. So then that mRNA target of the microRNA is not going to be made into protein. One way of thinking about micro RNAs is that they have some promiscuity where you could have one micro RNA that can interact with hundreds, even thousands of mRNA. And it's thought that micro RNAs can control about 60% of the proteome through this mechanism.
Nick JikomesSo the majority of proteins potentially in our cells, how much of that protein gets made is regulated or influenced to some degree by these types of RNAs.
Stephanie DawsYes, I would say influenced is a good word because there's many factors that contribute to gene expression.
Nick JikomesOK, so it's almost like people could imagine like it's like your genome could be unwound until like one into your chromosomes could be each unwound into a long string of DNA. But of course, these things are folded up in really complex ways, and they kind of unravel and fold in different ways. And that's important. But then when you have proteins that start making RNAs from the DNA, And these things can basically be different lengths. They could be one long string. They could sort of be like folded on themselves and then cut into pieces after they're folded. So it's almost like if you had like your shoelace, you tie your shoe into a knot, but then you could take a pair of scissors and like cut it in different ways. And the thing that you cut is going to have a certain shape and that's going to sort of dictate what all of these RNAs and things actually do.
Nick JikomesSo there's a lot of, there's a lot of folding and confirmation changes and cutting and The genome can be turned into RNAs of various kinds and processed into various shapes. And then all of those things have different functions based on their structure.
Stephanie DawsYes. And then also depending on the tissue and the cell type, there's going to be different expression of micro RNAs. It's not the same micro RNAs that are going to be expressed in the same profile in every single part of the brain or the body.
Nick JikomesAnd so this sounds like a very general thing too. It's not like special cells have micro RNAs and other ones don't really have them. It sounds like most cells and most creatures probably use these types of things to some degree.
Stephanie DawsYes.
Nick JikomesYeah. Yeah. And so, um, when we start to think about like reward processing and neuroplasticity, you know, I've covered neuroplasticity and the mesolimbic dopamine system on the podcast many times in different contexts, you know, talking about drugs of abuse of different kinds and so on and so forth. I don't know if we need to go over all of the details and review all of that here, but I think for this discussion, right, people can just understand. We learn, we remember, our behavior can change and it's modifiable. There's neuroplasticity that happens, right? Synapses can be formed, they can be broken, connections can be made, they can be pruned. Things change in the brain and that's part of how we adapt to our environment over time through learning.
Nick JikomesThe dopamine system is important for that. Different brain circuits are important for drug seeking and addiction and these things that we're going to talk about. But the way that these changes happen ultimately involves at some level gene expression changes. You have to increase gene expression, decrease gene expression, turn things on, turn things off. And these non-coding RNAs are an important facet of how some of these changes actually happen inside of cells. So I guess with all of that in mind, let's talk about what you study with respect to drug seeking behavior. We'll get to psychedelics, some of the work that you've done recently, but you often look at opioids and opioid addiction and withdrawal and then how psychedelics impact those things. What opioids do you study the most in the lab when you're doing animal research?
Nick JikomesWhich ones are you studying and why do you pick those ones?
Stephanie DawsA lot of the research from our lab has used heroin in an animal model of drug self-administration. And we've used heroin simply because many people have used that in labs in the past. And for a long time, the drug supply in the United States was dominated by heroin. However, that has since changed and now our drug market is primarily fentanyl or fentanyl analogs. There's been a big push to start changing some of the animal models and try to use other drugs that are found in the human population. So we also use fentanyl. We use another compound that is a fentanyl analog that's ultrapotent called furanofentanyl. And in each of these scenarios, we put a catheter into the jugular vein of an animal.
Stephanie DawsWe train them to press a lever. And they very quickly learn that that lever is going to give them an infusion of the opioid. So a lot of data on heroin and more and more data becoming available with fentanyl and some of these ultra potent fentanyl analogs.
Nick JikomesYeah. And to what extent, when we think about something like heroin versus fentanyl, they're both opioids, so they're going to have some commonality, but they're also different drugs, and they have different levels of potency, for example. Is fentanyl more or less just a very potent form of heroin, or is it different in other respects as well? Is it interacting with different receptors, and some of them are the same, or is it just really, really potent heroin?
Stephanie DawsI'm glad that you asked that because we just did an experiment to answer that question. So what we did is we tried to determine if we were to use a dose of fentanyl that resulted in similar amounts of motivation. for pressing the lever and receiving drug infusions, if we could find the dose of fentanyl that resulted in the same behavioral patterns as what we observe with heroin or the more potent fentanyl, analog fentanyl, do we see similar rates of drug taking behavior when the animals go through forced abstinence?
Stephanie DawsDo they have the same amount of drug-seeking behavior, because that could answer the question, is fentanyl causing people to have a harder time recovering? Is it causing more recurrence of use? Because we have had such a big surge in drug overdose deaths, and a lot of that is driven by fentanyl. We found that there was no difference once we created that dose that seem to have similar rates of drug taking behavior. So our conclusion is that the increased rate of overdose deaths from fentanyl is likely due to the increased potency, perhaps people not being as careful with it, not realizing how potent it is and using more than intended. But fentanyl does bind to the mu opioid receptor and it stays interacting with the receptor much longer than the metabolites of heroin do. So it is known that there are some differences in the interaction of the mu opioid receptor with fentanyl versus how the mu opioid receptor is going to interact with some of the metabolites of heroin once it enters the body.
Nick JikomesAnd this mu-opioid receptor, so it's one of the opioid receptors in the brain. And this is the main one involved in addictive opioids. So this is sort of like a common mechanism that all addictive opioids share. They bind to this mu-opioid receptor.
Stephanie DawsWhen they bind to the receptor, they induce feelings of euphoria, positive feelings. It gives you that high, and that is gonna be responsible for that release of dopamine and the nucleus accumbens and the reinforcement that causes people to like the drug.
Nick JikomesYeah. So basically, if you were to administer a drug, I'm sure people have done this, you administer a drug like fentanyl or heroin, but in the presence of a mu opioid receptor blocker, so it can't activate that particular receptor. I would imagine that gets rid of the reinforcing properties of the drug and people would not report the euphoria and the positive feelings that come with that drug normally.
Stephanie DawsRight. So antagonists of the mu opioid receptor are compounds like Narcan. They're going to cause very quickly for someone to have withdrawal symptoms and negative feelings.
Nick JikomesGot it.
Stephanie DawsSo that's blocking that euphoria.
Nick JikomesYeah. So that's literally what Narcan does. It's basically another molecule. And I imagine it gets in to the brain and it's basically just going to nudge away the opioid from that particular receptor.
Stephanie DawsTo answer your other question, though, about whether fentanyl does different things versus heroin, whether opioids do different things, that's the other part of our project that we're studying. There's a postdoc in my lab, Wickinson Norzay, and he's doing RNA sequencing right now to measure gene expression. in areas of the brain that are important for drug reward, and he's going to be determining what are the mRNAs and the microRNAs that are different in the brain after these various opioid agonists. So we want to understand if they're causing different signaling patterns, if they're activating different groups of genes, and to know whether or not they have similar or different effects.
Nick JikomesSo you give these drugs to animals or to humans. They're very reinforcing. They cause this euphoria, these positive feelings. An individual will want to do it again, and they often do. And there's neuroplasticity being stimulated by that. So synapses are getting strengthened, stuff is changing in the brain to make the animal more and more likely to keep doing that. the behaviors that led to the ingestion of the substance, and to do them compulsively moving forward. So there's lots of different paradigms people have used to study this in animals.
Nick JikomesIn terms of what's happening in the brain, so we know that plasticity is happening, we know that dopamine is involved in certain circuits, we know the mu opioid receptor is involved in the effects of these drugs. When it comes to the other things that you study, these micro RNAs, these non-coding RNAs, are those elements of biology important for the neuroplastic changes that you get induced with opioids and other reinforcing drugs?
Stephanie DawsAbsolutely. There is a micro RNA that we have been studying for a long time now called mirror 485 5P. And this micro RNA, it's activated very rapidly by activity. So when there's synaptic activity, this micro RNA is able to signal very rapidly. We've been looking at it in the context of how a micro RNA might be able to respond very quickly when there is a cue associated with a drug. and the individual has been abstinent for a long time. So very quickly, there's a signal that comes into the brain that might cause somebody to return to drug use. And we think microRNAs that are activated by synaptic activity might contribute to this.
Stephanie DawsThere's other microRNAs that are also important for the structure of the synapse that are going to be impacting For example, actin polymerization, how the synapse is inserting different receptors into the membrane so that there can be remembering of the drug-associated event, and that can also trigger more drug-taking behavior. Those are a couple of examples of how microRNAs might be important for plasticity.
Nick JikomesOkay, so they are very important. If you inhibit the production of some of these non-coding RNAs, does that prevent things like compulsive drug seeking? Does it really disrupt the reinforcement that these drugs can induce? Or are they just sort of like modulating things on the edges?
Stephanie DawsYeah, that's a good question. So if you think about how one microRNA can have many different targets, I think of microRNAs as being a way that you could manipulate a master regulator that may have pleiotropic effects. And when we think about many of the compounds that are used to treat different neuropsychiatric disorders, they may target many different receptors. So by manipulating one microRNA that is controlling many different genes, you may be able to control a host of different processes that are contributing to drug taking or seeking behavior.
Stephanie DawsThere's a number of groups in the addiction field that have manipulated micro-RNAs in discrete brain regions and looked at how that impacted drug taking and seeking. And there's individual micro-RNAs in distinct brain regions that have the ability to control such processes.
Nick JikomesAnd so opioids in general and fentanyl in particular, one of the reasons they're famous is they tend to be very addictive, even more reinforcing than other drugs in the animal models and in humans. Can you give us a sense for how addictive these drugs are compared to other drugs that people may have heard of? When you give these things to animals over and over again, do all of the animals engage in compulsive drug seeking, or is it half of them, 60% of them? How do those numbers look, and how do they compare to other drugs people may have heard of?
Stephanie DawsIt's really dependent on the dose that's used in the protocol. When you're using lower doses of the drug, you're not gonna have as many of the animals learning the behavior very rapidly. But if you use too much of the drug, it can also be aversive. So one technique that a lot of people use is a dose response curve, where they'll give a number of different doses, they'll look at the number of infusions and lever presses that the animal takes over those range of doses, and then try to determine what might be a dose that causes a lot of drug taking behavior, but doesn't cause aversive effects. When it comes to fentanyl and furanofentanyl, I would say we observe more rapidly the animals learning compared to heroin. And when you compare it to things like cocaine or methamphetamine, it's a little bit difficult to compare. I would say that cocaine might be easier to train animals on because I think it's also impacting It might be impacting some of the synaptic dopamine release in different mechanisms versus opioids.
Stephanie DawsHowever, when you look at the drug-seeking behavior long after abstinence, the animals that are trained to self-administer cocaine, they have those drug-seeking behaviors for much longer than they do for opioids. Now, whether this translates into humans, and those are the same patterns that are observed in humans, that I can't speak to because I'm not a medical doctor, but anecdotally, hearing people describe their experiences in going through opioid withdrawal, opioid withdrawal is very severe. It can oftentimes require hospitalization. And it's very, very serious.
Stephanie DawsThere are also individuals who can be abstinent for long periods of time, and then they return to drug use because the drug cravings are so strong.
Nick JikomesYeah, yeah. Yeah, I've had Christian Lucher on the podcast before, and he makes the distinction between, so he basically says addiction is compulsive drug seeking, but then also dependence. And withdrawal is very much connected to the dependence part. So some drugs, you have both. And some drugs, you only have one or the other. According to him, cocaine is very reinforcing. You'll see a lot of compulsive drugs seeking to a cocaine, but you don't get severe withdrawal symptoms like you do with an opioid. Animals don't get physically sick and just have a tear. They might want to do it again if it's around and they'll like to do it again, but they don't have those physical symptoms that seem to be pretty common with opioids. Can you talk a little bit more about the withdrawal with opioids and where those things actually come from? Why is it that people have gut issues and they have nausea and vomiting and things like that? Is that tied to how these drugs actually work in the brain?
Stephanie DawsYes, yes, definitely. Opioids cause constipation and they slow down gut transit. So when an individual is going through abstinence or detoxification, you're going to have an increase in that gut motility, diarrhea. There can oftentimes be vomiting. Insomnia is really common. Night sweats, a lot of physiological symptoms and oftentimes medications are given to manage the anxiety associated with having all those withdrawal symptoms if a patient is in an inpatient facility.
Nick JikomesYeah, and I'm not exactly sure how long those things last, but I get the impression that it can be some time, like days or maybe even weeks. I'm under the impression that opioid withdrawal can last a while, longer than I would imagine the drug is around. Is that true? Why is that? Why do these withdrawal symptoms last so long with these drugs?
Stephanie DawsWell, the body is also trying to recalibrate. After chronic drug use and having that dose of drug all the time, and then you remove that, you are really readjusting and you have to readjust your homeostasis. So there's a lot that happens over time that causes somebody to be addicted to a drug and then really recalibrating that can take a long time. But I think one thing that is important to emphasize is the negative feelings that occur during detoxification.
Stephanie DawsThere's activation of brain regions such as the amygdala. just for example, just one brain region, but there's brain regions that are going to cause a lot of dysphoria and it can be depression like symptoms or sadness. And that really drives people to continue using the drug because you want to alleviate some of those negative feelings. So you may have heard the term self-medicating. If you feel really bad, then you want to alleviate that. So it can be very easy to return to drug use to get rid of that withdrawal symptoms.
Nick JikomesGot it. So there can kind of be multiple phases to this. Initially, the drug feels good, and then you want the good feeling again. But as you get used to it and those feelings maybe dissipate somewhat, your body is becoming more used to the drug. You're becoming dependent on it. And then in its absence, you have these withdrawal symptoms. So now you're experiencing bad feelings, basically, when you're not on it. And so you kind of switch from brain kind of switches from, ooh, I like that, I want it again, to I feel terrible in the absence of this now that my brain and my body are used to it.
Nick JikomesAnd then you're basically going back to it in order to relieve those negative symptoms. And I would imagine in human beings, that's a huge factor in relapse. Definitely. And so when we think about treating opioids and addiction generally, but we'll talk about opioids in particular, you could imagine treating the sort of addiction and euphoria and drug-seeking side of it, dampening the rewarding effects of drugs or dampening the reinforcement effects that they have in the brain.
Nick JikomesYou could also imagine alleviating withdrawal symptoms in ways other than taking the drug again so that people don't have these sort of negative effects on the other side of it. and therefore they're less motivated to go back to the drug to alleviate those withdrawal symptoms. How do you think about that in terms of treatment in the lab? Is one of those sort of more attractive to you in the sense that it's easier to imagine how you would achieve that? Or does it even make sense to think of those as sort of two components to look at?
Stephanie DawsI'm glad that you asked that question because a lot of the ways in which We are examining relapse-like behavior and recovery or detoxification in the animal models. It's so different from how addiction, opioid addiction in particular, is treated. The most common medications for managing opioid use disorder are methadone, which is a full mu opioid receptor agonist, as well as buprenorphine. So with methadone, you are replacing the opioid that the individual was using, whether it was heroin, fentanyl, some other prescription medication, the individual is getting the methadone and it's reducing the craving.
Stephanie DawsPeople can overdose on methadone. It's a full agonist and it's going to reduce the craving that the individual may have. So then they may not go and seek out drugs illegally. it may allow them to manage their symptoms in a better way. But one idea is that it's similar to what would be referred to as a medication replacement therapy. And then the other one, buprenorphine, that's a partial agonist antagonist. So with buprenorphine, you have a little bit of a combined pharmacology going on, but also people have overdosed from buprenorphine. Buprenorphine is very important because it's not going to cause people to have that full agonist like methadone does.
Stephanie DawsSo it's going to interact differently with the opioid receptor. And it may help patients manage their symptoms in such a way that they don't have to take it every single day because there's long lasting versions of it. Methadone individuals have to get that every day. So it's a couple different ways in which opioid use disorder is treated. in human patients. And unfortunately, the animal models that we're using, we are not incorporating full mu opioid receptor agonists or even partial agonists into our recovery protocols on a daily basis. Oftentimes, we're looking at forced abstinence where an animal is placed into their home cage for a period of time, We may put them back into the chamber where they were self-administering a drug, and we don't give them the drug, but we measure the amount of times they may press a lever or nose poke to get the drug, but no drug is given to them.
Stephanie DawsSo it's not really the best way of measuring drug seeking behavior or relapse, but it's a very controlled way of doing it. And in preclinical labs, we have the ability to control all aspects of the animal's environment. We can remove some of the compounds and we can break down, isolate individual contributors to drug taking or seeking behavior. However, there's a push in more recent years to try to incorporate some of these compounds such as buprenorphine into our models to try to understand how buprenorphine is causing a reduction of drug taking or seeking behavior.
Stephanie DawsAnd are there other compounds that might assist buprenorphine and increase the efficacy of it? So that's an area of research that my lab is really interested in. because we want to take information from how opioid use disorder is managed in human patients and incorporate that into our models because oftentimes opioid use disorder is not treated as just abstinence only. There might still be other drug use or there can be compounds like methadone, which are causing activation of new opioid receptors.
Stephanie DawsAnd it's not really comparable to the complete forced abstinence that we have in our animal models.
Nick JikomesWhen we think about fentanyl versus heroin, traditional heroin, is So heroin comes ultimately from the opium poppy. Is it essentially like a plant extract of the opium poppy? How divorced from the plant is heroin? Or do you need to take an opium poppy, extract something, and then do something in a lab to make the heroin that people would inject? Or is it really a component of the plant? How does it tie in there?
Stephanie DawsYeah, so heroin can be synthesized in a lab. I believe it was first synthesized by the Bayer Company. Morphine can be derived from the poppy plant.
Nick JikomesGot it.
Stephanie DawsFentanyl is also synthesized in a lab as well.
Nick JikomesSo morphine can come directly from the opium poppy, but then there's another step or two to get to what we would call heroin. And then fentanyl, is it purely synthetic? Like they make it from scratch in a chemistry lab? Yes. Got it. And so what is, other than the fact that they both interact with the mu opioid receptor, are these things structurally similar to each other? Are they like the same class of compound or is fentanyl really a different beast chemically, but it also happens to act on the mu opioid receptor?
Stephanie DawsThere are structural similarities, but as I mentioned before, how they're interacting with the mu opioid receptor is going to be a little bit different. So heroin gets broken down and its metabolites are going to interact with the mu opioid receptor. Fentanyl will interact with the mu opioid receptor, but it's also binding to a different region of the mu opioid receptor and it's going to stay in there much longer. than heroin or morphine will. And it's thought that that extra time that fentanyl is interacting with the mucoid receptor might cause additional signaling mechanisms or longer signaling mechanisms than what might be seen with other opioids like morphine and heroin.
Nick JikomesYeah, yeah. So at the end of the day, no matter what drug we're talking about, if we're thinking about addiction and its treatment, reducing withdrawal symptoms, anything like that, we're going to be talking about a reconfiguration of the brain. The drug stimulates some kind of neuroplasticity, circuits change, synapses are made and broken, stuff changes. And some of those, there's going to have to be further changes or different changes to to reverse some of those changes. Things have to be undone or new changes have to come in to compensate for the ones induced by the drug in some capacity. People have been talking a lot lately about psychedelics and people have been doing a lot of research here. And one of the things that the psychedelics seem to do is enable the brain to engage in neuroplastic change more than it otherwise would. And so naturally you might think, okay, well, if this is sort of a neuroplasticity problem, someone who's addicted or an individual who's addicted or a mouse in a lab, their circuits have been reconfigured in a way by the drug that we need to change.
Nick JikomesSo we need to induce some kind of neuroplastic change so that they're not going to engage in this compulsive drug seeking anymore or that their withdrawal symptoms are lessened or what have you. How do you start to think about the psychedelics from the perspective of what you study in regards to opioid addiction? And how did you start to get into this part of what you do?
Stephanie DawsYeah, that's a great question. So many people are studying psychedelics right now, and it seems like they might be a cure-all for many different types of psychiatric disorders, many different conditions. I initially became interested in psilocybin because it interacted with the 5-HT2A receptor. That's the receptor for the serotonin 2A. I was interested in this because this gene is regulated by heroin self-administration. So we had done gene expression analysis after heroin administration. We had also compared it to a data set where we had activated the immune system of rats. And we looked to see, was there any overlap?
Stephanie DawsBecause our hypothesis is that there can be some inflammation or residual changes in gene expression by inflammation that are common to what is also observed after opioid exposure. And one of the genes that was in common was the serotonin 2A receptor.
Nick JikomesGot it. So you already knew this. You knew that when you give animals heroin and they self-administer it, it changes the expression of the serotonin 2A receptor. Correct. In which direction? Does it make it go up, down?
Stephanie DawsWe observed an up regulation.
Nick JikomesGot it.
Stephanie DawsSo we tried to determine if we could manipulate this receptor pharmacologically with either agonists like psilocybin or antagonists, could we change drug taking or seeking behavior? And my first thought was that perhaps if you are activating this receptor, maybe it's gonna cause more addiction because we saw an up-regulation of it after heroin self-administration. However, there's a lot of compensatory changes that happen with gene expression and protein expression, and it's really not clear, is there more serotonin 2A receptor with heroin, and that is what is observed in the gene expression, or is there a down-regulation of the protein, and then we have compensatory increases in gene expression.
Stephanie DawsThere's a lot of unknown there, and we haven't really delved into all of those different possibilities. The first thing that we just did is we gave rats psilocybin or an antagonist. We used a couple of different antagonists for the serotonin 2A receptor. And the reason behind this is because we were reading so much in the literature about how psilocybin might be good for impacting drug-seeking behaviors.
Nick JikomesSo, yeah, describe what you did exactly here. So I'm guessing that you're allowing animals to self-administer heroin and they start to do that more and engage in compulsive heroin seeking. And then at some point after that, you're giving them psilocybin. So what is the basic experimental setup here?
Stephanie DawsWell, the first thing that we did is we investigated whether psilocybin would reduce drug-taking behavior. We allow the animals to self-administer heroin, and then we gave them psilocybin to see if it caused them to stop taking the heroin. And these are experiments that were led by a former postdoc from my lab, Gabriel Flores. He's now at Yale University, and he's also continuing to study psilocybin in the context of other psychiatric disorders. When he gave psilocybin to the rats, he waited four hours to make sure that they weren't having a psychedelic episode or that they weren't impaired by the psychedelic. He didn't observe any changes in drug taking behavior though. So he waited another three weeks after they stopped taking heroin, and he gave them psilocybin prior to a relapse test. And with the relapse test, we put the animals back into the self-administration chamber, but they don't get any of the heroin.
Stephanie DawsWhen he pre-treated them with psilocybin, they had a big reduction in the amount of drug-seeking behavior that they exhibited. And he did this a couple of different times with different time points. He did a four-hour pretreatment. He even did a 24-hour pretreatment. And he did this in additional cohorts of rats to show that in animals that only received a single injection of psilocybin just right before the relapse test, they had a significant reduction in drug-seeking behavior when they were administered a three milligram dose of psilocybin.
Nick JikomesSo basically rats are allowed to self-administer heroin. They do that over and over again. They develop compulsive seeking of heroin. You then wait some amount of time, you give them a dose of psilocybin, and then you put them back in the heroin chamber and you look at how much effort or how much time they spend trying to get more heroin. And if they're given a dose of psilocybin, after they've already sort of been hooked on heroin, basically, they are less likely to self-administer. And basically, it looks like they're less likely to relapse in the future after they've already been hooked on heroin more or less.
Stephanie DawsYes, so we did this with a four hour and a 24 hour time point. There's an MD PhD student in my lab named Amy Stringer and she's continued this project. She's done this in female rats and she hasn't observed the same effect. She's really only seen this in male rats and she extended the time point out to 48 hours. It looks like the effect goes away when we go at longer time points. But she's also doing a couple of experiments that I think are really impactful for how psilocybin may be administered clinically. One of them is that she's testing microdosing. She did an experiment where she gave drug-naive rats a microdose of psilocybin, less than what would cause them to have a psychedelic experience, a tenth of the dose that Gabrielle had used.
Stephanie DawsAnd she looked at their overall gross behavioral activity, looking at memory tests, locomotor activity, depressive-like behavior. And she didn't observe big cognitive impairments in these rats, but she did observe an increase in some genes associated with synaptic plasticity. So she's now using the same protocol of microdosing in rats that have been trained to self-administer fentanyl. She's giving them fentanyl for 10 days.
Stephanie DawsAfter they self-administer fentanyl, then she's going to start a microdosing protocol when they're going through forced abstinence and examine whether the microdosing causes them to have a reduction in relapse behavior. And then the second, go ahead.
Nick JikomesKeep going, keep going.
Stephanie DawsShe also did another experiment where she trained them to self-administer fentanyl. And then she gave them one dose of the psilocybin, that larger three milligram dose before a relapse test. And she did not observe a reduction in drug seeking behavior. She waited and continued doing more of the relapse sessions on subsequent days. And she observed a significant reduction in relapse behavior over time. And that suggests that the psilocybin is accelerating extinction of the drug associated taking behavior. The other thing that she did is she gave them a primed injection of fentanyl so that they would remember that euphoric feeling associated with the fentanyl self-administration. And then she coupled this with a psilocybin administration.
Stephanie Dawsand determine that when the animals have that fentanyl priming, normally they reinstate their drug seeking behavior, but the animals that had the psilocybin, they did not have that reinstatement. So that would suggest that when somebody is exposed to the drug again, that perhaps they don't have as much of a motivation to start taking it again if they have had psychedelics.
Nick JikomesYeah. So there's a number of things to talk about there. Timing, dose, sex, and inflammation. Let's talk about each of those one at a time. So briefly, it sounds like you've observed sex differences here, which I've actually covered on the podcast before, including a very recent episode. And this should actually be unsurprising to anyone who's listening who's listen to the conversations about these things I've had on the podcast before. But it sounds like males and females do not respond the same way.
Stephanie DawsYes, that's what we've observed. I know there's other people that have studied psychedelics in rodents and observed sex differences as well. So I wasn't really surprised about that. I was a little bit disappointed though, because I think the therapeutic value of psychedelics is there. It would be nice if there was a drug that helped everybody, but there are a lot of differences in the biology, for different sexes, so there are probably different mechanisms that are going to contribute to drug-taking behavior. And we also see that with our other studies that we've done. We've done gene expression analysis after drug self-administration. in male and female rats.
Stephanie DawsAnd despite the fact that they have the same drug-taking behavior, we observe very big differences in their gene expression profile. So it's likely that there's different mechanisms that are contributing to the same behaviors.
Nick JikomesRight. So sometimes males and females don't respond the same way. One sex might respond in some way and one sex might not. And then in other cases, both sexes might respond behaviorally in the same kind of way to an intervention. But what's actually achieving that behavior change is different in terms of gene expression, brain changes, and all that stuff. Correct. I want to talk about dose as well. It sounds like the dose matters. You can get this helpful effect with the withdrawal symptoms with a fully psychedelic dose of psilocybin. It sounds like you don't know the answer yet for the micro dose, for the much smaller dose, but you do know that it's having some effect in the brain because you've measured things like gene expression. whether or not the behavior changes will be there, you can confirm for me, but you already know that the microdoses can cause something to happen in the brain because certain genes involved in information and other things are actually being changed by those small doses.
Stephanie DawsThat's correct with the microdoses. One comment about what you stated with the withdrawal effects, when we are looking at drug seeking behavior after forced abstinence, the animals have already gone through any type of withdrawal like behavior within the first two weeks. We're looking at three weeks after the last drug session, so they wouldn't be going through any withdrawal at that point. We do have other experiments going on in the lab though, where we are looking at how psychedelics may be impacting withdrawal right after the drug stops.
Stephanie DawsSo I have to reach back out to you to know how psychedelics are impacting withdrawal.
Nick JikomesOK, so that's a story for a different day. But just to make sure I'm following your. allowing the animals to administer heroin, you're basically getting them addicted to heroin. And then you're stopping, they can't get the heroin anymore. And then they go through their withdrawal and their unpleasant feelings, whatever the rodent experiences. And then after that, you're doing the psilocybin experiments and then seeing, do they engage in heroin seeking again? So you're not looking at the withdrawal symptoms per se, you're letting those happen, you're letting those go away and resolve, and then looking at heroin reinstatement after that.
Stephanie DawsRight. And the thought is, if someone can stop taking a drug, maybe they go through a detoxification program, a recovery program. There's something that causes people to return to drug use. And there are changes that happen in the drug free brain. that are contributing to continued drug taking behavior. And that is a big focus of what my lab tries to study, which is why we let the animals go through that three weeks of abstinence and then look at some of the mechanisms that happen long after the last drug exposure.
Nick JikomesYeah. And I want to talk now about what you... You mentioned inflammation and you measured... It might be a little subtle to people listening. You measured earlier expression changes after administering heroin. And you noticed among other things, presumably, that heroin induces an upregulation or increase in the expression of the 5HD2A receptor. And you mentioned something about compensation, because sometimes, you know, we make an intervention and we measure how gene expression changes, something might go up and we kind of think like, oh, the intervention caused it to go up. And maybe it did.
Nick JikomesBut sometimes the reason things go up is because some other change was instigated. And then this change that we're measuring is compensating for that other change. And you mentioned that the 5-HC2A receptor, the serotonin 2A receptor, the so-called psychedelic receptor, it goes up after you give animals heroin. you thought that heroin might be involved in stimulating some kind of inflammation in the brain. That makes me think about the work of Charles Nichols, who I've talked to on the podcast before, and he's found that classic psychedelics, including 5-HT2A receptor agonists, like psilocybin, I believe, and LSD, and some others, they're actually very potent anti-inflammatories through these serotonin receptors. And so this makes me think like, oh, like is heroin inducing some neuroinflammation and then the brain's trying to compensate by that by upregulating an anti-inflammatory type pathway. So I want you to talk about this inflammation stuff a little bit more. Let's just start with the raw effects of heroin.
Nick JikomesWhat is going on in terms of neuroinflammation after heroin is administered to animals in their brain?
Stephanie DawsThere is neuroinflammation that happens, and there's also data from humans that have overdosed from opioids. We know that there is a large upregulation of neuroinflammatory pathways related to TNF-alpha, NF-kappa B. Those human data sets really drive what we study in the lab. So because there's this neuroinflammation that individuals have after they've gone through a drug overdose, we wanted to understand if we observed those same things in our rodent model.
Stephanie DawsAnd there is some overlap that we observe after chronic heroin self-administration. There are genes related to TNF-alpha signaling and NF-kappa B that are upregulated. And we think that the long-lasting effect of opioid exposure in the brain is that there is this pro-inflammatory effect. When there is acute administration of opioids, there can be some anti-inflammatory effects. So It's really a balance of how long the drug exposure is. We also know that there are clinical trials that have been done and experimental studies where individuals have been given anti-inflammatory compounds, opioid-dependent individuals, and they do observe some impact on their drug-seeking and drug-taking behavior. So we know that targeting inflammatory pathways could be important for helping individuals recover from opioid dependence. And that is really the essence of why I was interested in psilocybin.
Stephanie DawsI read Charles's work, I'm a big fan of his, and seeing that psychedelics have the ability to dampen inflammatory signaling I put those two together and thought, well, maybe we can try to alleviate some of the opioid-induced neuroinflammation with psychedelics, and that can also reduce drug-taking or seeking behavior. So that's really the hypothesis that we're working under in my lab. We started to look into it in more detail by looking downstream of psilocybin activation.
Stephanie Dawswe did some gene expression analyzes comparing the rats that had reduced drug-seeking behavior after psilocybin to the ones that just took heroin. We wanted to know what are the genes that psilocybin is changing that could be causing this.
Nick JikomesSo in other words, you have a group of animals You do the heroin experiments, they're administering heroin, then you wait some time, you give them psilocybin. Some of those animals continue seeking the drug and some do not. So you've got sort of two different subpopulations here that you can look at because they're responding differently to the psilocybin intervention.
Stephanie DawsWe just compared the rats that had heroin alone versus those that had heroin plus psilocybin.
Nick JikomesOkay. Got it. Got it. Okay.
Stephanie Dawsto see what is it that psilocybin is doing that's causing these rats to have reduced drug-taking behavior. I'm sorry, drug-seeking behavior. And one of the genes that we observed regulated was the IL-17A cytokine. This is a pro-inflammatory cytokine, and it's been studied in the context of other opioid-induced behaviorals. I have a couple of colleagues here at Temple University, Scott Rawls and Sudet Anand. They published some really key papers in the field looking at how IL-17A signaling can be important for reducing some of the behavioral effects of opioid withdrawal or opioid analgesia. So we knew that there was some link between IL-17 and opioids, and we've started to pursue this in other ways by injecting animals with IL-17 antibody the same way we use psilocybin to determine if that could also reduce heroin-seeking behavior. And we observed very similar effects.
Stephanie DawsSo now what we're trying to do is link the psilocybin and the inflammation in more detail and try to determine what are the anti-inflammatory mechanisms of psilocybin. Are they all mediated through IL-17? Are there other cytokines and chemokines that come into play?
Nick JikomesYeah, yeah. And you've done some work recently on psilocybin, looking at how it reduces heroin seeking and looking at some of the gene expression changes in genes involving inflammation in key parts of the brain. Can you give us just a general sense of what you've seen so far? What are the brain regions you've looked at where you see changes and why are they important in this context? And what were some of those gene expression changes in particular?
Stephanie DawsWell, we started by looking at the prefrontal cortex and the nucleus accumbens. The nucleus accumbens is an obvious brain region because it's really important for reinforcement after chronic drug-taking behavior.
Nick JikomesYeah, this is what we think of as like the addiction circuit, right?
Stephanie DawsRight. A lot of people that study addiction, they oftentimes look in the nucleus accumbens. But we also looked in the prefrontal cortex because the prefrontal cortex is very important for some of the preoccupation behaviors associated with drug craving, some of the planning that goes into obtaining more drug. And the prefrontal cortex is also regulated by psilocybin in non-addiction models. So we know from human imaging studies, as well as models of depression-like behavior, that when animals are given psilocybin or humans, that the prefrontal cortex becomes engaged. So it's thought that the prefrontal cortex might be important for some of the perceived feelings that are caused by psilocybin administration, maybe dampening some of the brain areas that are involved in depressive-like behavior. Prefrontal cortex is very important for major depressive disorder. And we know that when animals are given psilocybin and looking at animal models of depression, that the prefrontal cortex is important because there are changes in synaptic plasticity there.
Stephanie Dawsthat are thought to relieve some of the depressive-like behaviors. So we looked at those two brain regions, the prefrontal cortex because it's been so well studied with psilocybin, and then also the nucleus accumbens. And what we observed were a handful of cytokines or chemokines that were regulated after psilocybin administration that were significantly different from animals that just had heroin alone. One of those was IL-17. We're looking in more detail now, especially in our model where we've given fentanyl versus fentanyl plus psilocybin to try to understand more about the inflammatory cytokines and chemokines that are regulated following psilocybin exposure.
Nick JikomesYeah, but it sounds like everything is more or less in alignment here. The psilocybin does seem to be having effects on genes involved in inflammation that are consistent with an anti-inflammatory effect generally.
Stephanie DawsThat's what we've observed, yes.
Nick JikomesYeah, yeah, yeah. Interesting. And so in the brain, just at a high level, what does inflammation look like and mean inside of the brain? Can you give people a sense for that? Does the tissue actually become enlarged and literally physically inflamed?
Stephanie DawsThat's a good question. So there are changes that happen to the cellular structure. There are other cells besides just neurons in the brain. There's microglia, there's astrocytes, those can both become activated and release cytokines and chemokines. There's also the blood-brain barrier that protects the brain from the blood supply and there can be perforations that happen in that blood-brain barrier. So there can be other substances from the periphery that get into the brain. That's thought to be one of the mechanisms by which opioids induce neural inflammation. There can be leakage from the gut and that can get through the blood-brain barrier and into the brain.
Stephanie DawsBut there's also a host of other things that can happen cellularly that contribute to sickness of some of the cells. There can be gene expression and protein changes associated with inflammation. So I mentioned TNF-alpha, NF-kappa B. There's also the neuroinflammosome, which is a host of many different genes and proteins that are related to inflammation that can be activated within neural tissue.
Nick JikomesInteresting. For the gene expression changes that you observe, have you guys dug into how that's happening? Does this involve micro RNAs and some of the RNA biology we started talking about earlier?
Stephanie DawsWe haven't investigated the relationship between psilocybin anti-inflammatory effects and micro RNAs, but that is definitely one possibility of how that could be occurring. Right now, we're looking at some of the cytokines and chemokines that are downstream of the serotonin 2A receptor activation. and trying to determine whether those changes are occurring at the level of protein regulation or if there are other epigenetic contributions that are happening. We really want to understand that link between psilocybin interacting with the serotonin 2A receptor and the corresponding gene expression and protein changes.
Nick JikomesYeah. And so 5-HT2A receptor, serotonin 2A, that receptor is famous for being the psychedelic receptor because when you block it and give a psychedelic, it kind of gets rid of the psychedelic effects. That's how people know it. Have you or anyone else done like an unbiased RNA-seq type of expression analysis on what happens inside of neurons in response to 5-HG2A receptor activation? Do we understand that certain types of gene programs get turned on in response to activating this receptor? And if so, is there any clear interpretation of what that receptor is turning on in terms of gene programs?
Stephanie DawsThat's a great question. I've had that experiment in my grant applications for many years now, but it hasn't been funded. I would love to get some support and be able to test those hypotheses.
Nick JikomesOkay. Well, we'll see what the NIH does about that. Interesting. Okay. What are you guys working on today in the lab? What are some of the questions tied into this stuff that you're pursuing right now?
Stephanie DawsI'm glad that you asked that because a lot of the work that we've been doing with non-coding RNAs has pivoted from preclinical models into human biomarker development. So we know that micro RNAs in the brain and the blood of rats has a relationship with the amount of drug taking or seeking behavior. But we also know that micro RNAs have been utilized in other disciplines for many, many years now as biomarkers. And with the invention of AI and the ability to do a lot of predictive modeling, microRNAs can even diagnose some types of cancer.
Stephanie DawsThey can predict diagnoses of Alzheimer's disease. So being able to detect microRNAs and the non-coding profile in the blood has a lot of power.
Nick JikomesHold on. You can detect micro RNAs in the blood. The level of micro RNA expression in the brain or some other tissue can be reflective in a serum of measurement of these things?
Stephanie DawsIt can, but it may not just be from the brain. It can be from other tissues as well. So there's different ways that you can isolate the microRNA in the blood where you can determine this is the profile just coming from the brain, or we don't care, this is just the profile overall coming from all the different tissues.
Nick JikomesGot it. But is the idea here, so I just wanna make sure I'm understanding the microRNA stuff. In general, microRNAs are going to dampen or inhibit the translation of some mRNA into a protein. So the overall level of a micro RNA will tell you something about that. So if some micro RNA goes up and you measure high levels of it in the serum, would that generally imply that there's a down regulation of the genes that are tied to that micro RNA?
Stephanie DawsNot necessarily because there's many things that go into play for gene expression regulation. I think that the microRNA is influencing its target gene expression, but it needs to be validated. A lot of the ways in which microRNA targets have been identified is through predictive algorithms, but really only a very small fraction of them have been experimentally validated. So more work would need to be done in order to say, yes, this microRNA is down. and then the corresponding mRNA target is up. Got it.
Nick JikomesSo when you look at the raw sequence of a micro RNA and you know its structure, you can guess what types of sequences on which genes are likely complimentary to that micro RNA and could be sensitive to it, but you have to actually go back in and validate that and measure it. And there's a lot more prediction that's been done and not as much validation of all of those predictions. Correct. Got it.
Stephanie DawsSo when it comes to the blood, there's a lot of things that I want to touch on here. Um, the first thing is a little bit about the biology of micro RNAs and how they're processed. So from the prime micro RNA structure, there's a three P and a five P micro RNA. And both of those are going to be, um, transcribed at the same time, but only one of them is going to be made into a mature micro RNA. So one possibility is that the other side, if it's the 5P that's made into the mature microRNA, perhaps it's the 3P that's not needed. The other ones, sometimes they are released into the bloodstream. That's one possibility. Other times, these microRNAs are moving around in the body via vesicles.
Stephanie DawsThey might be going from cell to cell. They may be released into the blood, there's a lot of unknowns about how they're trafficked through the body. But what we do know is that we can detect them in the blood, and there are relationships between human disease diagnoses and the blood microRNA profile. So this focus on biomarkers is a little bit different from our focus that we had in our animal model on micro RNA functions. So now we're not really looking at the function of the micro RNA in the blood. We just want to use it as a tool to try to understand a little bit more about diagnoses and treatment responsiveness.
Nick JikomesSo, and yeah, this is interesting. Let me just make sure I'm thinking about this correctly. So empirically, point blank, you can measure micro RNAs in the blood, they last long enough, they get secreted, they end up in the blood, you can measure them, they're there. It sounds like people have also definitely tied them to disease states, like certain disease states, you can measure a micro RNA profile in the blood, and it's fairly robust. Is that much true? Right. So, and when you say micro RNA profile in the blood, do you mean you're measuring one micro RNA that goes up in a disease state or is it a micro RNA profile like you're measuring a bunch of them and there's a pattern that seems to be tied to a particular disease or tissue state?
Stephanie DawsI mean, there's a pattern of them. There can be groups of them that are associated with given conditions.
Nick JikomesGot it. So the idea here, I guess, would be, if you've got, say, disease state X, that's going to involve some amount of gene expression change in some parts of the body. And the microRNAs might be reflecting this. So another way of saying that is, if you're measuring patterns of microRNA concentration in the blood, that's going to tell you something about gene expression in the body. they might tell you something in a way where you don't actually need to know what the particulars are, but it is kind of a readout of disease state X is present, not normal state Y.
Stephanie DawsCorrect.
Nick JikomesYes. Got it. And are these things... Does micro RNA profiling from the serum, does this offer any clear advantages? Like are these things particularly easy to measure? Is this like a robust signal? Intuitively, I would have thought like they're small RNAs, they're probably pretty fragile and flimsy, but am I wrong about that?
Stephanie DawsYes, they're more stable than mRNA. Because they're small, they don't have that poly-A tail that can be eaten up by RNAses. So they are, in general, they're more stable than mRNA. They're easy to detect in blood. You could do a simple qPCR test. So the ways in which microRNAs can be utilized for diagnoses for cancer, for example, if you had a patient's blood and you did a few PCRs on them, similar to how PCR was used as a tool to diagnose COVID. There are lots of PCR assays that were run all the time. I mean, they can be very rapidly run, so it could be another screening tool for different disease states.
Nick JikomesAnd the technology is there. And you can do this in a way where you're not just doing a PCR on one gene product. You can do a whole bunch of different gene products and get a more comprehensive profile of something that might be going on.
Stephanie DawsRight. But the way that we envision using this is not for diagnoses because we have urine drug screens that can tell us whether somebody is using drugs. People can admit it, right? There's a lot of different tools out there that are already readily available for diagnoses. What we want to understand is if these microRNAs can be predictive of drug relapse, recurrence of use in humans, whether a treatment is good for a patient, whether their craving is being managed. So really treatment responsiveness.
Nick JikomesYeah, I guess the idea would be, let's say you have two people who are recovering fentanyl addicts. Maybe one of them is going to be much more predisposed to relapse than the other one. Maybe they don't realize that. Maybe they're ashamed of it and they don't want to tell someone that. You might be able to detect these things in the form of these measurements you can make from their blood that reflect something like a difference in their brain circuitry that's going to make one person more likely to relapse than another.
Stephanie DawsWell, my thought was that if there are different medications for managing opioid use disorder, people may do better on one versus another. Anecdotally, I've heard that patients may do better on buprenorphine versus methadone. Are there differences where somebody could be started on a compound right away? Are there dose relationships where we can determine the right dose faster so that we set somebody up for success.
Nick JikomesYeah. Yeah. And this isn't directly related to our conversation, but you got me thinking about other things now. So when we're thinking about these micro RNA profiles that you can measure in the blood, if gene expression changes tied to micro RNA profiles can be predictive of certain disease or tissue states, could this type of serum measurement be a way to less invasively and perhaps more preemptively make certain diagnoses than we could otherwise. So for example, let's say I've got, I don't know, some kind of tumor forming in my brain or somewhere in my body. And one way to know that would be to go biopsy that, but that's difficult, that's highly invasive, that might come with serious risk. In theory, could something like this micro RNA profiling from serum measurements be used to see that type of change without having to go in and do that type of biopsy?
Stephanie DawsYes, yes, exactly. And that's one of the utilities for it in the field of cancer. So I'm glad that you mentioned that because I'm going to shift a little bit and talk about one other project that we're working on and it would involve using micro RNAs for that type of tool. We have a collaboration with OBGYN and pediatrics to recruit women who are using opioids during pregnancy and then collect some blood from their infants after they've been delivered.
Stephanie DawsAnd the goal is to collect the blood look at microRNA biomarkers and see if they allow us to determine high versus low risk for neonatal abstinence syndrome, withdrawal, severity, NICU hospitalizations, because the blood is already taken anyways when infants are born, and it can be used for a variety of tests, but it's just standard that this blood is taken. So is there a way that we could say yes, this infant is high risk, they've had this much exposure during pregnancy, we need to make sure that we give them a little bit more pharmacological care, or there needs to be a different way in which we are approaching the care of this infant versus one that might be lower risk.
Stephanie DawsAnd the reason behind that is because staying in the NICU, staying in the hospital, those are really traumatic things, especially if you have just given birth, there's a lot of issues going into whether or not the parent is going to be able to take the child home because they've been using drugs, so there may be calls to child protective services. There's a lot of things that go into it. It's a very stressful situation, but if an infant is low risk and they're not going to have any withdrawal, then maybe they don't need as many invasive tests.
Stephanie DawsSo to try to reduce some of the stimulation and help them recover from the opioid exposure versus an infant that may be high risk is going to need a lot more supportive care that may need a longer stay in the hospital then you have the ability to make that decision fairly rapidly because the withdrawal that infants experience during neonatal abstinence syndrome, it may not happen immediately after delivery. It can be delayed sometimes depending on the route of opioid use during pregnancy. It can be like five days later.
Stephanie DawsSo it doesn't always happen right away when the infant is born and having some tool that can help guide Diagnostically, the decisions that are made during this really critical period is how I would envision this biomarker strategy being utilized.
Nick JikomesGot it. So I think the big takeaway here for me is. these micro RNAs, this RNA biology, you can take a simple blood serum measurement, do some relatively simple PCR, simple for the people who know how to do it. And you can infer gene expression profiles that are going to be tied to things like disease states. And you can do that relatively non-invasively. And you can do that in a more preemptive fashion to know things faster than you'd otherwise be able to know them. Interesting. Are there any final thoughts you want to leave people with or anything you want to reiterate from our discussion today, especially as it relates to opioid addiction and how that interfaces with psychedelics and gene expression and neuroplasticity?
Stephanie DawsI just want to emphasize how important this research is. There's a lot of people that are suffering from addiction, whether it's the individuals themselves, their families, their children. There's many people that are affected by drug use, and it's something that we as a society need to come together and really support. either further research or trying to understand ways in which we can help support these individuals. And secondly, I just think having the collaboration between doctors who are treating patients with opioid use disorder or other substance use disorder, their dialog with basic scientists like myself is really, really critical. Because if we want to move the field forward, then we need to be having these conversations about how opioid use disorder is treated, how are we modeling this with our animals, just making sure that we are studying the best things possible to try to understand the human condition, because that's really what's gonna drive the field forward and possibly identify new therapies for our patients.
Nick JikomesAll right, well, Stephanie Dawes, fascinating research. I look forward to following what you're doing in the near future, and thank you again for your time. Thank you very much for having me. Hey, everyone. A great way to support my efforts is to visit my support page at mindandmatter.substack.com. A link to that page is in the episode description, or you can search for it on the Substack page itself. The support page has an up-to-date list of my affiliate partners. These are companies I work with, and if you buy those products through those links or using the discount codes provided, those will get you a great deal on a variety of products related to optimizing physical, metabolic, or mental health and vitality.
Nick JikomesThese are all products I use Myself and some of them are directly related to podcast episodes or formulated by mind and matter guests For example, there's a great product called keto Citra formulated by a kidney biologist who is on episode number 186 it contains the ketone body BHB together with several minerals in a precise ratio Formulated with kidney health in mind. There are also links to products like physical technology devices to track your metabolic activity health, digital applications to help you find and learn about food and consumer products, and more. One product I use every day is the AquaTrue water filter.
Nick JikomesI recommend this to everyone because it gets everything out of your drinking water, heavy metals, microbes, endocrine disruptors, microplastics, you name it. Other charcoal or gravity-based filters that a lot of people use don't get everything out, they just get some of the stuff out. So I really like the AquaTrue product. You can look for a link to my affiliate partners on my support page or directly in the episode description to this episode, or you can go to mindandmatter.substack.com to find it there.
Send us Fan Mail At 93, Artemis Simopoulos explains why oils once used in paint now dominate the food supply, how a high omega-6 intake slows the making of EPA and DHA, and why cholesterol-lowering corn oil did not...
Send us Fan Mail Keith Baar explains why tendons stop adapting after 10 minutes of loading, why long low-load holds beat fast reps for connective tissue, and how vitamin C, collagen, caffeine and mTOR shape training....
Send us Fan Mail Dr. Stephen O'Rahilly explains GDF15, a stress hormone that makes us feel sick and eat less, and why morning sickness, and its severe form hyperemesis gravidarum (HG), comes from GDF15 made by the...
Send us Fan Mail Robin Carhart-Harris explains why his trial of psilocybin therapy vs. the SSRI escitalopram for depression missed one primary measure but favored psilocybin on almost everything else, and why SSRIs can...
Send us Fan Mail Nick talks with Prof. Gary Lewin (Max Delbrück Center, Berlin) about naked mole-rats, which in lab tests survived 18 minutes in pure nitrogen by shutting down brain activity, keeping the heart beating,...